DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the DIVI S LABORATORIES LTD (DIVISLAB) share price today?

DIVI S LABORATORIES LTD (DIVISLAB) is trading at ₹7,247.5 on the NSE, down 0.94% on the day. Source: DocStoX.

What is the PE ratio of DIVI S LABORATORIES LTD?

DIVI S LABORATORIES LTD has a price-to-earnings (PE) ratio of 74.9 in the Healthcare sector.

What is the market capitalisation of DIVI S LABORATORIES LTD?

DIVI S LABORATORIES LTD has a market capitalisation of approximately ₹1,92,406 crore.

DIVI S LABORATORIES LTD

F&O

DIVISLAB·NSE·Healthcare

₹7,247.50▼ -68.50 (-0.94%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY NEXT 50NIFTY 100NIFTY 200

Day₹7200.00

₹7316.50

52W₹5637

₹739092%

Open

₹7316.00

High

₹7316.50

Low

₹7200.00

Prev Close

₹7316.00

Volume

4.55L

VWAP

₹7252.17

Snapshot

Key fundamentals

Market Cap

₹1.92L Cr

P/E Ratio

74.93Expensive

P/B Ratio

10.72

EPS

₹96.73

Book Value

₹631.00

ROE

16.50%Strong

ROCE

22.00%Efficient

Dividend Yield

0.44%

Debt / Equity

0.00Low

Face Value

₹2.00

52W High

₹7390.00

52W Low

₹5636.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹857

▼ 88.2%downside

Trading at ₹7,248 — 88% above our estimate

BearFair valueBull

₹729₹857₹1,172

/100

Business quality — Solid

Growth 46Profitability 79Efficiency 35Valuation 50

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Expensive — trades at 75× earnings

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)
Promoters hold a controlling stake

Risks

Expensive — trades at 75× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

17% ROE fading to 12% over ~10 yrs, on ₹631 book

₹770

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹1,172

Analyst target

No analyst coverage

—

Blended fair value₹857

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)
Promoters hold a controlling stake

Bear case

Expensive — trades at 75× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

74.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

16.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1.92L Cr

P/B

10.72

EPS

₹96.73

Div Yield

0.44%

What changed

Recent changes

Domestic institutions+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 74.9×

Growth

Steady

+11% rev CAGR

Profitability

Healthy

16.5% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %60.9%

Turnover₹33001.75L Cr

Trades49,411

VWAP₹7252.17

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.8%

+8.7%

10Y

+10.8%

Profit

+12.1%

+5.3%

10Y

+8.6%

EPS

+12.1%

+5.3%

10Y

+8.6%

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 39.0%

Watch-outs

Cons

Stock is trading at 10.8 times its book value
The company has delivered a poor sales growth of 8.67% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Domestic institutions added 0.25 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

51.9%0.00

Public

8.5%-0.07

FII / FPI

20.2%-0.09

DII

19.4%+0.25

Quarterly trend

Ownership over time

Q1 FY27

Promoter51.88%

FII20.20%

DII19.38%

Public8.54%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

F&O